Oseltamivir Mercury Pharmaceuticals Limited (Oseltamivir Phosphate)

Oseltamivir phosphate, the active ingredient in Oseltamivir Mercury Pharmaceuticals Limited, is a neuraminidase inhibitor presented as a oral formulation for systemic use. It treats influenza A and B infections in adults and children. GNH USA supplies Oseltamivir Mercury Pharmaceuticals Limited as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Oseltamivir Mercury Pharmaceuticals Limited as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oseltamivir phosphate is an antiviral medication that acts on influenza viruses.

- Treatment of influenza A and B: Reduces symptom duration and may lessen complications in confirmed cases. - Post‑exposure prophylaxis of influenza: Prevents illness when administered shortly after exposure to the virus. - Seasonal influenza control: Used in public‑health programs to limit spread during outbreaks.

Oseltamivir is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional episodes, often transient. - Headache: mild headache reported by some patients. - Diarrhea: loose stools, usually self‑limiting. - Abdominal pain: mild discomfort in the stomach area.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Neuropsychiatric events: unusual behavior, delirium, or hallucinations, reported mainly in pediatric cases. - Liver enzyme elevation: occasional increase in hepatic transaminases. - Renal impairment worsening: accumulation of active drug in patients with kidney dysfunction. - Stevens‑Johnson syndrome: rare severe skin reaction.

Oseltamivir should be used with caution in specific populations and conditions.

- Renal function: dose adjustment may be required for patients with reduced kidney function. - Pregnancy: safety not established; weigh potential benefits against risks. - Breastfeeding: unknown safety; consider infant exposure through milk. - Age considerations: pediatric dosing differs from adult dosing; follow prescriber guidance. - Drug interactions: review concomitant medications for potential interactions. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Oseltamivir may interact with other medicines, requiring monitoring.

Major Interactions (Avoid): - Probenecid: may increase oseltamivir plasma levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Antiviral combination therapy: concurrent use with other neuraminidase inhibitors can affect efficacy. - Live attenuated influenza vaccine (LAIV) administration: timing should be coordinated. - Warfarin: potential alteration of INR . - Zanamivir: overlapping antiviral activity may require dose adjustment. - Acid‑reductant S